Luke Rothermel
Surgical Oncology · Cleveland, OHNPI 1801113873
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,000 of the $4,085 with a category attached, or 73.4%. Polynovo North America LLC accounts for 81.3% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $3,377, more than ten times the $136 reported in 2019.
Across 16 payments — averaging $255.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Polynovo North America LLC$3K
- Davol Inc.$440
- E.r. Squibb & Sons, L.L.C.$173
- Kerecis Limited$72
- Johnson & Johnson$53
- Aroa Biosurgery Incorporated$14
- plus $13 from 1 others
Across 22 payments — averaging $6464.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$76K
- E.r. Squibb & Sons, L.L.C.$67K
What the payments were for
- Consulting fees$3,00073%
- Travel & lodging$2737%
- Food & beverage$81220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Polynovo North America LLC | 4 | $3,320 |
| Davol Inc. | 3 | $440 |
| E.r. Squibb & Sons, L.L.C. | 2 | $173 |
| Kerecis Limited | 3 | $72 |
| Johnson & Johnson | 2 | $53 |
| Aroa Biosurgery Incorporated | 1 | $14 |
| Myovant Sciences Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Novosorb BTM$3,273
- ARISTA AH FLEXITIP$156
- PROGEL$148
- PHASIX$136
How this compares
$4,085 in reported general payments places this provider in the 80th percentile of 69 surgical oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tramadol Hcl | 79 | $72 |
| Metronidazole | 15 | $53 |
| Lorazepam | 11 | $4 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Cleveland
- John AmmoriCleveland$6K
- Samer NaffoujeCleveland$4K
- Julie LangCleveland$3K
- Jordan WinterCleveland$2K
- Richard HoehnCleveland$1K
- Benjamin LiCleveland$400
- Joseph SkitzkiCleveland$287
- Stacy KowalskyCleveland$255
- Regina Matar-UjvaryCleveland$253
- Tasadooq HussainCleveland$219
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.